中国医药导报
中國醫藥導報
중국의약도보
CHINA MEDICAL HERALD
2015年
21期
122-125
,共4页
幽门螺杆菌相关性慢性胃炎%益生菌%三联疗法%临床效果
幽門螺桿菌相關性慢性胃炎%益生菌%三聯療法%臨床效果
유문라간균상관성만성위염%익생균%삼련요법%림상효과
Helicobacter pylori associated chronic gastritis%Probiotics%Triple therapy%Clinical effect
目的：观察益生菌联合三联疗法治疗幽门螺杆菌相关性慢性胃炎的临床效果及预后。方法选择深圳市石岩人民医院2013年3月~2014年1月收治的幽门螺杆菌相关性慢性胃炎患者110例作为研究对象，并将其按奇偶数随机分为对照组（50例）和治疗组（60例）。对照组给予单纯三联疗法（奥美拉唑40 mg，2次/d+克拉霉素0.5 g，2次/d+阿莫西林1.0 g，2次/d）治疗；治疗组在此基础上加用益生菌（双歧杆菌乳杆菌三联活菌片，1片/次，3次/d）。观察比较两组治疗4周后临床效果及不良反应发生情况，随访1年后，观察复发率。结果对照组痊愈13例，显效18例，有效11例，总有效率为84.0%；治疗组痊愈22例，显效25例，有效11例，总有效率为96.7%，治疗组总有效率显著高于对照组，差异有统计学意义（P<0.05）；随访1年后，治疗组复发率（6.7%）显著低于对照组（22.0%），差异有统计学意义（P<0.05）。对照组有6例（12.0%）出现不良反应，其中恶心2例，呕吐1例，头晕3例；治疗组有2例（3.3%）出现不良反应，其中恶心1例，头晕1例，两组不良反应发生率比较差异无统计学意义（χ2=1.89，P>0.05）。结论益生菌联合三联疗法治疗幽门螺杆菌相关性慢性胃炎效果良好，并可有效降低复发率。
目的：觀察益生菌聯閤三聯療法治療幽門螺桿菌相關性慢性胃炎的臨床效果及預後。方法選擇深圳市石巖人民醫院2013年3月~2014年1月收治的幽門螺桿菌相關性慢性胃炎患者110例作為研究對象，併將其按奇偶數隨機分為對照組（50例）和治療組（60例）。對照組給予單純三聯療法（奧美拉唑40 mg，2次/d+剋拉黴素0.5 g，2次/d+阿莫西林1.0 g，2次/d）治療；治療組在此基礎上加用益生菌（雙歧桿菌乳桿菌三聯活菌片，1片/次，3次/d）。觀察比較兩組治療4週後臨床效果及不良反應髮生情況，隨訪1年後，觀察複髮率。結果對照組痊愈13例，顯效18例，有效11例，總有效率為84.0%；治療組痊愈22例，顯效25例，有效11例，總有效率為96.7%，治療組總有效率顯著高于對照組，差異有統計學意義（P<0.05）；隨訪1年後，治療組複髮率（6.7%）顯著低于對照組（22.0%），差異有統計學意義（P<0.05）。對照組有6例（12.0%）齣現不良反應，其中噁心2例，嘔吐1例，頭暈3例；治療組有2例（3.3%）齣現不良反應，其中噁心1例，頭暈1例，兩組不良反應髮生率比較差異無統計學意義（χ2=1.89，P>0.05）。結論益生菌聯閤三聯療法治療幽門螺桿菌相關性慢性胃炎效果良好，併可有效降低複髮率。
목적：관찰익생균연합삼련요법치료유문라간균상관성만성위염적림상효과급예후。방법선택심수시석암인민의원2013년3월~2014년1월수치적유문라간균상관성만성위염환자110례작위연구대상，병장기안기우수수궤분위대조조（50례）화치료조（60례）。대조조급여단순삼련요법（오미랍서40 mg，2차/d+극랍매소0.5 g，2차/d+아막서림1.0 g，2차/d）치료；치료조재차기출상가용익생균（쌍기간균유간균삼련활균편，1편/차，3차/d）。관찰비교량조치료4주후림상효과급불량반응발생정황，수방1년후，관찰복발솔。결과대조조전유13례，현효18례，유효11례，총유효솔위84.0%；치료조전유22례，현효25례，유효11례，총유효솔위96.7%，치료조총유효솔현저고우대조조，차이유통계학의의（P<0.05）；수방1년후，치료조복발솔（6.7%）현저저우대조조（22.0%），차이유통계학의의（P<0.05）。대조조유6례（12.0%）출현불량반응，기중악심2례，구토1례，두훈3례；치료조유2례（3.3%）출현불량반응，기중악심1례，두훈1례，량조불량반응발생솔비교차이무통계학의의（χ2=1.89，P>0.05）。결론익생균연합삼련요법치료유문라간균상관성만성위염효과량호，병가유효강저복발솔。
Objective To observe the clinical curative effect and prognosis of probiotics combined with triple therapy for Helicobacter pylori associated chronic gastritis. Methods One hundred and ten cases of patients with Helicobacter pylori associated chronic gastritis admitted to Shiyan People's Hospital of Shenzhen City from March 2013 to January 2014 were randomly divided into control group (50 cases) and treatment group (60 cases) according to odd-even num-ber. The control group was only given single triple therapy (Omeprazole 40 mg, twice a day + Clarithromycin 0.5 g, twice a day +Amoxicillin 1.0 g, twice a day); while on basis of control group, the treatment group was added with pro-biotics (Live Combined Bifidobacterium and Lactobacillus Tablets, once 1 tablet, 3 times a day). The clinical effect and adverse reactions after treatment for 4 weeks of the two groups were observed and compared, after follow-up for one year, the recurrence rate was observed. Results In the control group, there were 13 cases of cure, 18 cases of excellent, 11 cases of valid, the total effective rate was 84.0%; in the treatment group, there were 22 cases of cure, 25 cases of excellent, 11 cases of valid, the total effective rate was 96.7%. The total effective rate of treatment group was higher than that of control group, the difference was statistically significant (P<0.05). After follow-up for one year, the recur-rence rate (6.7%) of treatment group was lower than that of control group (22.0%), the difference was statistically signif-icant (P<0.05). There were 6 cases of adverse reactions in the control group, among which, there were 2 cases of nau-sea, 1 case of emesis, 3 cases of dizziness;there were 2 cases of adverse reactions in the treatment group, among which, there was 1 case of nausea, 1 case of dizziness, there was no statistically significant difference of adverse reactions be-tween the two groups (χ2=1.89, P>0.05). Conclusion Probiotics combined with triple therapy in the treatment of Heli-cobacter pylori associated chronic gastritis has a good effect, and it can effectively reduce the recurrence rate.
